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Collagen matrix wound dressings 
and the treatment of DFUs
O Objective: To obtain clinical evidence on the use of a collagen wound dressing in patients with 
diabetic foot ulcers (DFUs).
O Method: A convenience sample of patients managed in the podiatry outpatient clinic over an 8-month 
period were included in the evaluation, if their DFUs were not progressing. All participants received 
traditional adjunctive wound care as part of their treatment. Wound surface-area measurements and 
imaging of patients was carried out on a regular basis to allow the tracking of wound healing.
O Results: Six patients, with seven wounds were included in this study. There was an overall decrease in 
wound surface area over time. Three patients showed a relatively swift reduction in wound area, while 
one patient showed a slight increase in wound area. The percentage decrease in wound area levelled out 
quite quickly in three patients, with a mean wound duration of 14 months compared with 7.3 months in 
the remaining four wounds. One patient died of an unrelated cause.
O Conclusion: This case series evaluation provides a snapshot of experience at one clinical centre and 
the treatment of DFUs, and suggests that an active biological collagen dressing may support progression 
to healing by modulating the wound environment.
O Declaration of interest: S. Haycocks and P. Chadwick received supplies of ProHeal from MedSkin 
Solutions Dr Suwelack for use on patients in this evaluation. K.F. Cutting is a consultant to MedSkin 
Solutions Dr Suwelack and received a honorarium for his participation. MedSkin Solutions Dr Suwelack 
did not have any editorial control in the production of this manuscript.
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 T he tissues of the human body may be characterised functionally into two main groups: those that manage bodily proc-esses and undertake maintenance and repair functions, and those that form the 
major structural component of the body—the 
extracellular matrix (ECM) tissue. The ECM is 
primarily !brous in nature and comprises polysac-
charides, such as hyaluronan, and native polymers, 
such as collagen, elastin, proteoglycans and 
!bronectin, among others.1 All of these compo-
nents are dynamic in nature; they are synthesised, 
modi!ed and arranged by the cells that they sup-
port and sustain. It is important to note that the 
ECM plays an integral role in daily cellular activity 
and in tissue regeneration. 
Human skin is composed of three distinct layers: 
the epidermis, which is the outermost layer, the der-
mis, which lies directly beneath and is separated 
from the epidermis by the basement membrane, and 
the subcutaneous layer or hypodermis. Connective 
tissue within the dermal layer provides skin with its 
physical strength and function; these attributes of 
the dermis arise as a result of collagen, which is 
responsible for up to 80% of the dry weight of the 
dermis.2 Dermal collagen is composed primarily of 
type I (80–85%) and type III (8–11%) collagens.3
Within the dermis, the ECM not only provides 
physical structural support for dermal cells but also 
acts as a binding site/reservoir for a host of chemical 
messengers, growth factors and active molecules 
that are released following tissue injury to help 
stimulate cellular migration, recruitment into the 
wound site and proliferation.4
The majority of the ECM is formed of collagen.2 
Collagen is a ubiquitous protein found in connec-
tive tissue, blood vessels and the skin. It is synthe-
sised by !broblasts and has an extensive role to play 
in the wound healing process, including chemotax-
is of !broblasts and keratinocytes. Collagen is either 
directly or indirectly involved in each of the four 
phases of wound healing:4,5
O Haemostasis, through platelet activation, is one 
of collagen’s most prominent functions6
O During the in#ammatory response, collagen 
in#uences cellular mitogenesis, differentiation 
and migration7
O A key part of the proliferative phase involves 
!broblasts laying down structural proteins of the 
ECM, including collagen. The cells and the ECM 
interact closely and continually, stimulating each 
other during the proliferative phase4
O During the !nal phase of wound healing (matura-
tion/remodelling) !broblasts continue to lay 
down collagen.8 Additional covalent cross-linking 
of collagen molecules helps to remodel the wound 
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It is evident that collagen is fundamental to suc-
cessful wound closure. What is not so clear is the 
magnitude of collagen’s in#uence within the total 
repair process.
Chronic wounds
Wounds that fail to heal in a timely manner and do 
not effectively respond to orthodox management 
practices using accepted protocols are classi!ed as 
‘chronic wounds’.10 Chronic wounds display a con-
siderably higher level of protease expression than 
acute wound healing,11 with elevated levels of pro-
teases,9 pro-in#ammatory cytokines and reactive 
oxygen species (ROS) found.12 Conversely, tissue 
inhibitors of metalloproteinases (TIMPs), which in 
normal wound healing limit matrix metalloprotein-
ase (MMP) function, tend to be present at lower lev-
els in chronic wounds.13
The persisting low level of in#ammation, which 
can typify chronic wounds, results in a reduction in 
the deposition of the ECM proteins, such as colla-
gen, while any ECM that the !broblasts do manage 
to lay down in the wound bed is at a greater than 
normal risk of being broken down by the unchecked 
activity of the MMPs.3 This constant struggle to 
deposit and maintain a fully-functioning ECM is a 
problem that needs to be addressed clinically. 
Wound treatments with ECM substitutes, such as 
acellular collagen matrices, look to mimic the struc-
tural and functional characteristics of healthy ECM 
and offer a biological approach to accelerate the 
healing process.14 Such matrices can be placed 
directly onto the wound to help expedite healing by 
acting as a wound scaffold.
Mechanism of action
When used in acute situations, such as breast recon-
struction or hernia repair, biological implants, such 
as acellular collagen matrices, are believed to 
become fully incorporated into the new tissue; how-
ever, when used in chronic wounds these matrices 
never fully integrate into the tissues and are ulti-
mately displaced.15 It is thought that placement of 
these acellular biological matrices into the chronic 
wound bed helps modulate the wound environ-
ment by acting as a biological cover, which facili-
tates wound healing.16
While the exact mechanism of action for biologi-
cal dressings remains unclear, it is thought to be 
multifaceted. Collagen-based matrices are thought 
to in#uence or contribute to wound healing in a 
variety of ways. These can include the provision of 
growth factors to the wound bed, maintaining a 
biochemically-balanced, moist wound environ-
ment, and the provision of a physical, structural 
support to facilitate tissue regeneration.17 In addi-
tion, a number of pre-clinical studies have suggested 
its bene!ts in wound healing may also include:
O MMP inhibition or deactivation7
O Stimulation of angiogenesis18
O Act as a chemoattractant for endothelial cells19 
and !broblasts20
O Provide a scaffold, which facilitates !broblast 
ingrowth and attachment,21 and the formulation 
of granulation tissue22
O The protection and/or donation of growth factors 
to the wound.18
Despite the growing knowledge base surrounding 
collagen and its use in biological dressings, the exact 
mechanisms of action and the roles played by acel-
lular matrices in chronic-wound healing have yet to 
be fully understood and de!ned. 
Collagen in advanced wound care
A considerable variety of collagen-based products 
currently exist for use in advanced wound care. 
For simplicity,  these products can be broadly cat-
egorised as either ‘allografts’ or ‘xenografts’. Allo-
grafts are tissue from one animal species that is 
transplanted into the same animal species; there-
fore, in this instance, collagen-based matrices 
derived from human cadaver skin are examples of 
allografts. Xenografts are tissue from one animal 
species that is transplanted into a different animal 
species, such as collagen matrices derived from 
porcine, bovine or equine sources, which are 
placed into a human wound.
As part of the tissue engineering process, cells 
within the harvested tissue are typically removed in 
order to minimise any potential host immune 
response, such as immunological rejection. This 
decellularisation results in an acellular collagen 
matrix that, as far as possible, retains its original/
native structure and function. The greater the com-
patibility between the acellular collagen matrix and 
the host ECM, the less risk of an adverse reaction.23 
Currently available acellular collagen matrices can 
vary widely between manufacturers (Table 1).24,25
Table 1. Acellular collagen matrices
Product format
Powder, gel, paste, mesh/sheet, "eece
Collagen source
Human, bovine, equine, porcine, avian, piscean, ovine
Product offering
Collagen only 
Chemically cross-linked collagen 
Collagen combined with (silicone membrane, 


























It is extremely dif!cult, if not impossible, to design 
and manufacture synthetic tissue that can compre-
hensively replicate the functionality of native tis-
sue. Therefore, it is suggested that collagen-based 
biological wound therapies consisting of natively-
structured collagen are best able to provide the 
desired functions of promoting cell adhesion, cellu-
lar growth and support of cell migration.26
ProHeal (MedSkin Solutions Dr Suwelack) is a ster-
ile, biological matrix that comprises of natively-
structured bovine collagen !bres, provided as a 
three-dimensional (3D), open-pore matrix. It is indi-
cated for all wounds healing through secondary 
intention, where the wound bed is free of devital-
ised necrotic tissue, including acute traumatic and 
surgical wounds, and chronic wounds, such as dia-
betic foot ulcers (DFUs), venous leg ulcers, pressure 
ulcers and ulcers of mixed aetiology. 
Debridement of the wound bed is recommended 
prior to application of the collagen matrix. Sharp 
debridement may result in bleeding of the soft tis-
sue; however, native collagen has demonstrated 
haemostatic properties,27 so application to freshly 
debrided wounds is permitted. Avoidance of chemi-
cal cross-linking ensures that the collagen will be 
resorbed, although residues may remain on the 
wound bed.28 The rate of application of the collagen 
matrix dressing may vary with the volume of 
exudate produced but on average twice weekly 
treatment is anticipated.
Interactions between cells and their micro-envi-
ronment is a feature of the healing process.29 Respons-
es to such interactions include cellular differentia-
tion, dedifferentiation and proliferation, and lead to 
the cellular structure and function associated with 
dermal tissue. Observation of these processes has led 
to the concept of dynamic reciprocity, encompassing 
the enduring and bidirectional cellular/ECM interac-
tion.29 In collagen matrix dressings, native collagen 
replaces the ECM and also acts as a scaffold for granu-
lation tissue growth and migration. 
The close similarity between the native collagen 
!brous structure of human dermis and the dressing 
(Fig 1) lends support to the use of native collagen, 
where chemotaxis of !broblasts and keratinocytes 
will support cellular growth and migration. Wound 
closure is achieved with complete re-epithelialisa-
tion following the migration of keratinocytes over 
the granulation tissue. The migration of keratinoc-
ytes is strongly associated with expression of colla-
gen IV.30 It is thought that stimulation of collagen IV 
expression takes place following the diffusion of 
collogen matrix dressing peptides, potentially accel-
erating wound closure (personal communication 
with Dr R. Bauer, Regensburg, Germany).
The aim of this evaluation was to appraise the use 
of an active biologic wound therapy, a collagen 
wound dressing (ProHeal) on a convenience sample 
of patients with slow-to-heal DFUs.
Method
A convenience sample of patients presenting at Sal-
ford Royal NHS Foundation Trust, UK and managed 
in the podiatry outpatient clinic between Octo-
ber  2011 and August 2012 were included in the 
evaluation, if their DFUs were not considered to be 
progressing, with the wounds showing little change 
in appearance in the wound bed and the size 
remaining static for a period of at least 3 weeks. The 
aim of the treatment was to ‘kick start’ healing, 
where wound healing appeared to have stalled.
Treatment protocol
All participants received traditional adjunctive 
wound care as part of their treatment. Holistic care 
of the patient focused speci!cally on pressure relief/
of#oading of the ulcerated area, appropriate for 
their foot and wound type. Wound-bed preparation 
prior to application of the collagen matrix included 
regular debridement and management of exudate 
levels. Infection was deemed to be present by record-
ing the following criteria: redness, pain, oedema, 
heat, swelling, malodour and/or the presence of 
osteomyelitis.31 Systemic antibiotics were used 
concomitantly, if judged necessary by the invest-
igators. Pain was managed through administration 
of appropriate analgesics.
Dressing changes were undertaken according to 
local clinical practice (usually three times per week). 
Patients were seen once a week by podiatry services, 
with other dressing changes carried out by district 
nurses or the patient themselves. 
The collagen matrix dressing was applied directly 
over the entire wound bed. In wounds with little or 
no exudate, the dressing was moistened with nor-
mal saline. Secondary dressings used were Melolin 
(Smith & Nephew), Allevyn adhesive (Smith & 
Nephew), Biatain (Coloplast) and sorbion sachet S 
(sorbion), to maintain a moist wound environment. 
Fig 1. Transmission electron microscopy images of structure  
of human dermis and the collagen matrix dressing
Human dermis Collagen matrix



































































At dressing change, any residual collagen matrix 
was left in the wound. Patients received the collagen 
matrix dressing, until application was stopped at 
the discretion of the lead clinician. 
The Eykona wound measurement system was 
used to provide accurate and repeatable measure-
ment of wounds throughout the evaluation. This 
system has been evaluated in clinical studies of 
diabetic ulcers and shown to have very low intra- 
and inter-assessor variability.32,33 In this evaluation 
it was used to provide wound surface-area measure-
ments. Imaging of patients was carried out on a 
regular basis to allow the tracking of wound heal-
ing. Once acquired, image data were assessed local-
ly. Data can also be assessed remotely, immediately 
or retrospectively to allow for additional measure-
ment information to be acquired. 
Results
Six male patients, all with type II diabetes mellitus 
and peripheral neuropathy were included in the 
study. Three patients were diagnosed with periph-
eral arterial disease. The median age was 59  years 
(range 54–82 years). One patient had a foot ulcer on 
both his left and right feet. The median wound 
duration was 12 months (range 2–18 months). Exu-
date levels were low in two patients and moderate 
in four patients (!ve wounds).
Patients received a variety of dressings prior to 
treatment with the collagen matrix dressing. These 
included various polyurethane foams, Hydro!ber, 
Mextra (Mölnlycke), sorbion sachet  s (sorbion), 
Biatain (Coloplast), Kerramax (Crawford Health-
care), Granugel (ConvaTec), Flaminal (Crawford 
Healthcare), Actisorb Silver 220 (Systagenix), Ina-
dine (Systagenix), Aquacel (ConvaTec), Acticoat 
Absorbent (Smith & Nephew), negative pressure 
wound therapy (NPWT) and larvae debridement 
therapy (LDT).
O Patient 1 an 82-year-old male presented with a 
DFU of 12 months’ duration on his left foot, with 
moderate wound exudate. Treatment prior to colla-
gen matrix included NPWT, foam dressings, antimi-
crobial dressings, and intravenous (IV) antibiotics 
vancomycin and piperacillin/tazobactam for osteo-
myelitis. Adjunctive therapies included Darco’s 
orthopaedic shoe with a total contact insole and 
weekly debridement.
O Patient 2 a 58-year-old male with a left foot DFU 
of 12 months’ duration, with moderate wound exu-
date. Prior treatment included NPWT, superabsorb-
ent dressings, and IV antibiotics meropenem and 
daptomycin for extensive osteomyelitis in the cal-
caneus. Adjunctive therapies included ROM Walker 
and weekly debridement.
O  Patient 3 a 59-year-old male with DFUs on 
both his left and right feet, of 12 months’ duration. 
Both ulcers had a moderate level of exudate. Prior 
treatment included antimicrobial dressings, foam 
dressings and a superabsorbent dressing. Adjunc-
tive therapies included bilateral slipper casts and 
Derby sandals.
O Patient 4 a 55-year-old male with a DFU on his 
right foot of 18  months’ duration, with moderate 
level of wound exudate. Previous treatment includ-
ed superabsorbent and antimicrobial dressings. 
Adjunctive therapies included ROM Walker and 
weekly debridement.
O Patient 5 a 54-year-old male with a DFU on his 
right foot of 2 months’ duration (Fig 2a), and a low 
level of wound exudate. Previous treatment  includ-
ed a wound contact layer and antimicrobial dress-
ing. Adjunctive therapies included slipper cast and 
Derby sandals.
O Patient 6 a 74-year-old male with a DFU on his 
left foot of 3  months’ duration (Fig  3a), with low 
wound exudate. Prior treatment included a hydrocol-
loid-based gel, wound contact layer, antimicrobial 
dressing, LDT, and oral antibiotics clindamycin and 
cipro#oxacin for osteomyelitis. Adjunctive therapies 
included Derby sandals with total contact insole.
Outcomes
An overall decrease in wound surface area over time 
was observed following introduction of the collagen 
matrix dressing, with three patients (3, 5 and  6) 
showing a relatively swift reduction in wound area 
(Fig  2b; Fig  4). Wound volume was not formally 
measured in this evaluation. Although patient  4 
showed a slight increase in wound area, it was esti-
a
Fig 2. Patient 5, showing the DFU of 2 months’ duration at study start (a) and 
after 3 weeks’ treatment with the collagen matrix wound dressing (b)
b
a
Fig 3. Patient 6 presented with a wound containing about 30% slough at the 
start of treatment (a); this devitalised tissue may account for the modest 

























mated that wound volume decreased as the wound 
was judged to be shallower at day 65 compared with 
day 1 of the evaluation process. The slight increase 
in wound area is most likely a consequence of the 
patient’s early return to work and non-concordance 
with the ROM walker. 
The collagen matrix dressing is intended for use on 
wounds where the wound bed has been adequately 
prepared and is devoid of any devitalised tissue. One 
patient (patient 6) wound contained 30% slough at 
the start of treatment. This devitalised tissue may 
have been responsible for the relatively slow progress 
made with this wound and account for the modest 
decrease (20%) in wound area (Fig 3b).
All other wounds appeared to have a healthy 
wound bed with granulation tissue of 100%. 
Sadly, patient 6 died of an unrelated cause at day 61 
of the evaluation. 
When examining the percentage change in 
wound area over time, the cohort of patients 
appear to divide into two distinct groups (Fig 4). 
The percentage change in wound area in patients 1, 
2 and  4 levels out quite quickly. These three 
patients’ wounds had an average duration of 
14 months compared with the other four wounds, 
whose average duration was 7.25  months. This 
supports the observation that longer standing 
wounds are slower to progress. Patients 3 (left and 
right), 5 and  6, whose wounds showed a higher 
percentage change in area, had all received a topi-
cal antimicrobial dressing prior to commencing 
treatment with the collagen matrix. Patient  5 
healed after 7 weeks’ treatment.
Discussion
Management of stalled wounds is a challenge faced 
by clinicians on a regular basis. It is estimated that 
15% of diabetic patients develop a neuropathic foot 
ulcer and 15% of these patients will eventually 
undergo an amputation.34 Recurrence of foot ulcers 
in patients with diabetes is high,35 and mortality 
rates in diabetics with a history of foot ulceration 
can be up to 49%.36 The challenge is to !nd an 
effective treatment that will close the ulcer in a 
timely fashion, to avoid the risk of infection and 
associated morbidity. The patients recruited to this 
evaluation were considered to be representative of 
DFU patients encountered in a hospital outpatient 
clinic. The results of this small-scale evaluation 
suggest that the collagen matrix dressing is suitable 
for application in DFUs when the wound bed has 
been adequately prepared. 
In a clinical investigation of 40 patients compar-
ing ProHeal with standard therapy in patients with 
venous leg ulcers, Romanelli and colleagues37 found 
that 85% of patients treated with the collagen 
matrix dressing showed a greater than 50% increase 
in granulation tissue formation at 4 weeks and con-
cluded that ProHeal was safe and ef!cacious in 
hard-to-heal venous leg ulcers when compared with 
the control group.
Limitations
The evaluation comprised of a series of six patients 
with seven DFUs recruited as a convenience sample, 
with no inclusion or exclusion criteria applied. Data 
collection ceased when application of the collagen 
matrix dressing was stopped, at the discretion of the 
lead clinician. Therefore, the longer-term implica-
tions of wound resolution following application of 
the dressing cannot be assessed. Nonetheless, the 
data collection does capture real-world experience 
of a collagen matrix and avoids the arti!ciality that 
is imposed by a randomised controlled trial. 
Conclusion
Although our understanding of the role of collagen 
in the skin and in the repair process has been 
described, comprehensive insight has yet to be 
acquired. Collagen matrices have a number of 
potential roles to play in the repair process includ-
ing; act as a scaffold to support tissue formation, 
chemotaxis of endothelial cells, stimulation of 
angiogenesis, promote !broblast attachment, 
provide and protect growth factors and to promote 
the normal wound healing process by modulating 
the wound environment. This case series eval-
uation  provides a snapshot of experience at one 
clinical centre. It is recommended that a more 
robust case cohort investigation into the impact of 
the collagen matrix dressing in the management of 
DFUs is undertaken. Q
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